Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients

JM Beveren, Gabriëlle Buitendijk, Sigrid Swagemakers, LC (Lianne) Krab, CH Roder, L de Haan, Peter van der Spek, Ype Elgersma

Research output: Contribution to journalArticleAcademicpeer-review

43 Citations (Scopus)
4 Downloads (Pure)


Background: Recent studies have suggested that deregulated AKT1 signaling is associated with schizophrenia. We hypothesized that if this is indeed the case, we should observe both decreased AKT1 expression as well as deregulation of AKT1 regulated pathways in Peripheral Blood Mononuclear Cells (PBMCs) of schizophrenia patients. Objectives: To examine PBMC expression levels of AKT1 in schizophrenia patients versus controls, and to examine whether functional biological processes in which AKT1 plays an important role are deregulated in schizophrenia patients. Methods/Results: A case-control study, investigating whole-genome PBMC gene expression in male, recent onset (, 5 years) schizophrenia patients (N = 41) as compared to controls (N = 29). Genes, differentially expressed between patients and controls were identified using ANOVA with Benjamini-Hochberg correction (false discovery rate (FDR) = 0.05). Functional aspects of the deregulated set of genes were investigated with the Ingenuity Pathway Analysis (IPA) Software Tool. We found significantly de Conclusions: We show significantly decreased PBMC gene expression of AKT1 in male, recent-onset schizophrenia patients. Our observations suggest that decreased PBMC AKT1 expression is a stable trait in recent onset, male schizophrenia patients. We identified several AKT related cellular processes which are potentially affected in these patients, a majority of which play a prominent role in current schizophrenia hypotheses.
Original languageUndefined/Unknown
Article numbere32618
JournalPLoS One (print)
Issue number2
Publication statusPublished - 2012

Cite this